Merck & Company, Inc. (NYSE:MRK)‘s stock had its “buy” rating reaffirmed by research analysts at BMO Capital Markets in a research report issued to clients and investors on Friday, September 8th. They currently have a $72.00 price objective on the stock. BMO Capital Markets’ target price would suggest a potential upside of 8.83% from the company’s current price.
Several other research firms have also recently commented on MRK. Jefferies Group LLC reaffirmed a “sell” rating and issued a $52.00 target price on shares of Merck & in a research report on Sunday, August 20th. J P Morgan Chase & Co raised their target price on shares of Merck & from $74.00 to $76.00 and gave the stock an “overweight” rating in a research report on Thursday, May 11th. Credit Suisse Group dropped their target price on shares of Merck & from $75.00 to $74.00 and set an “outperform” rating for the company in a research report on Wednesday, August 30th. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Vetr raised shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 target price for the company in a research report on Monday, May 15th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $70.00.
Shares of Merck & (NYSE MRK) traded up 0.06% during trading on Friday, reaching $66.16. The company had a trading volume of 14,685,767 shares. The company has a market cap of $180.44 billion, a price-to-earnings ratio of 35.82 and a beta of 0.81. The firm has a 50 day moving average price of $63.41 and a 200 day moving average price of $63.72. Merck & has a 12 month low of $58.29 and a 12 month high of $66.80.
Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The company had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. During the same quarter in the prior year, the company earned $0.93 EPS. The firm’s revenue was up .9% on a year-over-year basis. Analysts predict that Merck & will post $3.87 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “BMO Capital Markets Reiterates “Buy” Rating for Merck & Company, Inc. (MRK)” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.truebluetribune.com/2017/09/16/merck-s-mrk-buy-rating-reaffirmed-at-bmo-capital-markets.html.
Several institutional investors and hedge funds have recently bought and sold shares of MRK. Stock Yards Bank & Trust Co. boosted its holdings in shares of Merck & by 7.5% in the first quarter. Stock Yards Bank & Trust Co. now owns 53,798 shares of the company’s stock worth $3,418,000 after buying an additional 3,765 shares during the last quarter. First National Bank of Mount Dora Trust Investment Services boosted its holdings in shares of Merck & by 23.9% in the first quarter. First National Bank of Mount Dora Trust Investment Services now owns 66,505 shares of the company’s stock worth $4,226,000 after buying an additional 12,840 shares during the last quarter. Forte Capital LLC ADV boosted its holdings in shares of Merck & by 5.6% in the first quarter. Forte Capital LLC ADV now owns 21,424 shares of the company’s stock worth $1,361,000 after buying an additional 1,130 shares during the last quarter. GW&K Investment Management LLC boosted its holdings in shares of Merck & by 4.7% in the first quarter. GW&K Investment Management LLC now owns 408,948 shares of the company’s stock worth $25,985,000 after buying an additional 18,340 shares during the last quarter. Finally, Gulf International Bank UK Ltd lifted its holdings in Merck & by 1.9% during the first quarter. Gulf International Bank UK Ltd now owns 861,540 shares of the company’s stock valued at $54,742,000 after purchasing an additional 15,700 shares in the last quarter. 73.02% of the stock is currently owned by institutional investors.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Company Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.